id	sid	tid	token	lemma	pos
cord-263258-qpzaehg0	1	1	key	key	JJ
cord-263258-qpzaehg0	1	2	:	:	:
cord-263258-qpzaehg0	1	3	cord-263258-qpzaehg0	cord-263258-qpzaehg0	NN
cord-263258-qpzaehg0	1	4	authors	author	NNS
cord-263258-qpzaehg0	1	5	:	:	:
cord-263258-qpzaehg0	1	6	Montastruc	Montastruc	NNP
cord-263258-qpzaehg0	1	7	,	,	,
cord-263258-qpzaehg0	1	8	François	François	NNP
cord-263258-qpzaehg0	1	9	;	;	:
cord-263258-qpzaehg0	1	10	Thuriot	Thuriot	NNP
cord-263258-qpzaehg0	1	11	,	,	,
cord-263258-qpzaehg0	1	12	Samuel	Samuel	NNP
cord-263258-qpzaehg0	1	13	;	;	:
cord-263258-qpzaehg0	1	14	Durrieu	Durrieu	NNP
cord-263258-qpzaehg0	1	15	,	,	,
cord-263258-qpzaehg0	1	16	Geneviève	Geneviève	NNP
cord-263258-qpzaehg0	1	17	title	title	NN
cord-263258-qpzaehg0	1	18	:	:	:
cord-263258-qpzaehg0	1	19	Hepatic	hepatic	JJ
cord-263258-qpzaehg0	1	20	disorders	disorder	NNS
cord-263258-qpzaehg0	1	21	with	with	IN
cord-263258-qpzaehg0	1	22	the	the	DT
cord-263258-qpzaehg0	1	23	use	use	NN
cord-263258-qpzaehg0	1	24	of	of	IN
cord-263258-qpzaehg0	1	25	remdesivir	remdesivir	NNP
cord-263258-qpzaehg0	1	26	for	for	IN
cord-263258-qpzaehg0	1	27	coronavirus	coronavirus	NNP
cord-263258-qpzaehg0	1	28	2019	2019	CD
cord-263258-qpzaehg0	1	29	(	(	-LRB-
cord-263258-qpzaehg0	1	30	COVID-19	COVID-19	NNP
cord-263258-qpzaehg0	1	31	)	)	-RRB-
cord-263258-qpzaehg0	1	32	date	date	NN
cord-263258-qpzaehg0	1	33	:	:	:
cord-263258-qpzaehg0	1	34	2020	2020	CD
cord-263258-qpzaehg0	1	35	-	-	HYPH
cord-263258-qpzaehg0	1	36	07	07	CD
cord-263258-qpzaehg0	1	37	-	-	HYPH
cord-263258-qpzaehg0	1	38	25	25	CD
cord-263258-qpzaehg0	1	39	journal	journal	NN
cord-263258-qpzaehg0	1	40	:	:	:
cord-263258-qpzaehg0	2	1	Clin	Clin	NNP
cord-263258-qpzaehg0	2	2	Gastroenterol	Gastroenterol	NNP
cord-263258-qpzaehg0	2	3	Hepatol	Hepatol	NNP
cord-263258-qpzaehg0	2	4	DOI	DOI	NNP
cord-263258-qpzaehg0	2	5	:	:	:
cord-263258-qpzaehg0	2	6	10.1016	10.1016	CD
cord-263258-qpzaehg0	2	7	/	/	SYM
cord-263258-qpzaehg0	2	8	j.cgh.2020.07.050	j.cgh.2020.07.050	NNP
cord-263258-qpzaehg0	2	9	sha	sha	NNP
cord-263258-qpzaehg0	2	10	:	:	:
cord-263258-qpzaehg0	2	11	65c63d665f492ae622524d5c9d74c5eb69ed588f	65c63d665f492ae622524d5c9d74c5eb69ed588f	NNP
cord-263258-qpzaehg0	2	12	doc_id	doc_id	CD
cord-263258-qpzaehg0	2	13	:	:	:
cord-263258-qpzaehg0	2	14	263258	263258	CD
cord-263258-qpzaehg0	2	15	cord_uid	cord_uid	NNS
cord-263258-qpzaehg0	2	16	:	:	:
cord-263258-qpzaehg0	3	1	qpzaehg0	qpzaehg0	NN
cord-263258-qpzaehg0	4	1	nan	nan	NNP
cord-263258-qpzaehg0	4	2	Remdesivir	Remdesivir	NNP
cord-263258-qpzaehg0	4	3	is	be	VBZ
cord-263258-qpzaehg0	4	4	a	a	DT
cord-263258-qpzaehg0	4	5	nucleotide	nucleotide	JJ
cord-263258-qpzaehg0	4	6	analog	analog	NN
cord-263258-qpzaehg0	4	7	prodrug	prodrug	NN
cord-263258-qpzaehg0	4	8	with	with	IN
cord-263258-qpzaehg0	4	9	antiviral	antiviral	JJ
cord-263258-qpzaehg0	4	10	activity	activity	NN
cord-263258-qpzaehg0	4	11	against	against	IN
cord-263258-qpzaehg0	4	12	a	a	DT
cord-263258-qpzaehg0	4	13	broad	broad	JJ
cord-263258-qpzaehg0	4	14	spectrum	spectrum	NN
cord-263258-qpzaehg0	4	15	of	of	IN
cord-263258-qpzaehg0	4	16	human	human	JJ
cord-263258-qpzaehg0	4	17	coronavirus	coronavirus	NN
cord-263258-qpzaehg0	4	18	in	in	IN
cord-263258-qpzaehg0	4	19	cell	cell	NN
cord-263258-qpzaehg0	4	20	cultures	culture	NNS
cord-263258-qpzaehg0	4	21	and	and	CC
cord-263258-qpzaehg0	4	22	mouse	mouse	NN
cord-263258-qpzaehg0	4	23	models	model	NNS
cord-263258-qpzaehg0	4	24	including	include	VBG
cord-263258-qpzaehg0	4	25	SARS	SARS	NNP
cord-263258-qpzaehg0	4	26	-	-	HYPH
cord-263258-qpzaehg0	4	27	CoV-2	CoV-2	NNP
cord-263258-qpzaehg0	4	28	.	.	.
cord-263258-qpzaehg0	5	1	Recently	recently	RB
cord-263258-qpzaehg0	5	2	,	,	,
cord-263258-qpzaehg0	5	3	the	the	DT
cord-263258-qpzaehg0	5	4	Food	Food	NNP
cord-263258-qpzaehg0	5	5	and	and	CC
cord-263258-qpzaehg0	5	6	Drug	Drug	NNP
cord-263258-qpzaehg0	5	7	Agency	Agency	NNP
cord-263258-qpzaehg0	5	8	(	(	-LRB-
cord-263258-qpzaehg0	5	9	FDA	FDA	NNP
cord-263258-qpzaehg0	5	10	)	)	-RRB-
cord-263258-qpzaehg0	5	11	and	and	CC
cord-263258-qpzaehg0	5	12	the	the	DT
cord-263258-qpzaehg0	5	13	European	European	NNP
cord-263258-qpzaehg0	5	14	Medicines	Medicines	NNPS
cord-263258-qpzaehg0	5	15	Agency	Agency	NNP
cord-263258-qpzaehg0	5	16	(	(	-LRB-
cord-263258-qpzaehg0	5	17	EMA	EMA	NNP
cord-263258-qpzaehg0	5	18	)	)	-RRB-
cord-263258-qpzaehg0	5	19	recommended	recommend	VBD
cord-263258-qpzaehg0	5	20	remdesivir	remdesivir	NNP
cord-263258-qpzaehg0	5	21	for	for	IN
cord-263258-qpzaehg0	5	22	the	the	DT
cord-263258-qpzaehg0	5	23	treatment	treatment	NN
cord-263258-qpzaehg0	5	24	of	of	IN
cord-263258-qpzaehg0	5	25	patients	patient	NNS
cord-263258-qpzaehg0	5	26	hospitalized	hospitalize	VBN
cord-263258-qpzaehg0	5	27	with	with	IN
cord-263258-qpzaehg0	5	28	severe	severe	JJ
cord-263258-qpzaehg0	5	29	COVID-19	covid-19	JJ
cord-263258-qpzaehg0	5	30	infection	infection	NN
cord-263258-qpzaehg0	5	31	.	.	.
cord-263258-qpzaehg0	6	1	1	1	CD
cord-263258-qpzaehg0	6	2	,	,	,
cord-263258-qpzaehg0	6	3	2	2	CD
cord-263258-qpzaehg0	7	1	In	in	IN
cord-263258-qpzaehg0	7	2	the	the	DT
cord-263258-qpzaehg0	7	3	remdesivir	remdesivir	NNP
cord-263258-qpzaehg0	7	4	clinical	clinical	JJ
cord-263258-qpzaehg0	7	5	development	development	NNP
cord-263258-qpzaehg0	7	6	program	program	NN
cord-263258-qpzaehg0	7	7	,	,	,
cord-263258-qpzaehg0	7	8	some	some	DT
cord-263258-qpzaehg0	7	9	cases	case	NNS
cord-263258-qpzaehg0	7	10	have	have	VBP
cord-263258-qpzaehg0	7	11	raised	raise	VBN
cord-263258-qpzaehg0	7	12	concerns	concern	NNS
cord-263258-qpzaehg0	7	13	regarding	regard	VBG
cord-263258-qpzaehg0	7	14	a	a	DT
cord-263258-qpzaehg0	7	15	potential	potential	JJ
cord-263258-qpzaehg0	7	16	hepato	hepato	JJ
cord-263258-qpzaehg0	7	17	-	-	HYPH
cord-263258-qpzaehg0	7	18	biliary	biliary	JJ
cord-263258-qpzaehg0	7	19	disorders	disorder	NNS
cord-263258-qpzaehg0	7	20	associated	associate	VBN
cord-263258-qpzaehg0	7	21	with	with	IN
cord-263258-qpzaehg0	7	22	remdesivir	remdesivir	NNP
cord-263258-qpzaehg0	7	23	,	,	,
cord-263258-qpzaehg0	7	24	including	include	VBG
cord-263258-qpzaehg0	7	25	in	in	IN
cord-263258-qpzaehg0	7	26	healthy	healthy	JJ
cord-263258-qpzaehg0	7	27	volunteers	volunteer	NNS
cord-263258-qpzaehg0	7	28	and	and	CC
cord-263258-qpzaehg0	7	29	patients	patient	NNS
cord-263258-qpzaehg0	7	30	with	with	IN
cord-263258-qpzaehg0	7	31	COVID-19	COVID-19	NNP
cord-263258-qpzaehg0	7	32	.	.	.
cord-263258-qpzaehg0	7	33	3	3	CD
cord-263258-qpzaehg0	8	1	In	in	IN
cord-263258-qpzaehg0	8	2	cohort	cohort	NN
cord-263258-qpzaehg0	8	3	studies	study	NNS
cord-263258-qpzaehg0	8	4	of	of	IN
cord-263258-qpzaehg0	8	5	patients	patient	NNS
cord-263258-qpzaehg0	8	6	hospitalized	hospitalize	VBN
cord-263258-qpzaehg0	8	7	for	for	IN
cord-263258-qpzaehg0	8	8	severe	severe	JJ
cord-263258-qpzaehg0	8	9	COVID-19	covid-19	NN
cord-263258-qpzaehg0	8	10	who	who	WP
cord-263258-qpzaehg0	8	11	were	be	VBD
cord-263258-qpzaehg0	8	12	treated	treat	VBN
cord-263258-qpzaehg0	8	13	with	with	IN
cord-263258-qpzaehg0	8	14	compassionate	compassionate	JJ
cord-263258-qpzaehg0	8	15	-	-	HYPH
cord-263258-qpzaehg0	8	16	use	use	NN
cord-263258-qpzaehg0	8	17	remdesivir	remdesivir	NNS
cord-263258-qpzaehg0	8	18	,	,	,
cord-263258-qpzaehg0	8	19	hepatic	hepatic	JJ
cord-263258-qpzaehg0	8	20	enzyme	enzyme	NN
cord-263258-qpzaehg0	8	21	elevated	elevate	VBN
cord-263258-qpzaehg0	8	22	were	be	VBD
cord-263258-qpzaehg0	8	23	the	the	DT
cord-263258-qpzaehg0	8	24	most	most	RBS
cord-263258-qpzaehg0	8	25	frequent	frequent	JJ
cord-263258-qpzaehg0	8	26	adverse	adverse	JJ
cord-263258-qpzaehg0	8	27	drug	drug	NN
cord-263258-qpzaehg0	8	28	reaction	reaction	NN
cord-263258-qpzaehg0	8	29	reported	report	VBD
cord-263258-qpzaehg0	8	30	.	.	.
cord-263258-qpzaehg0	9	1	4	4	LS
cord-263258-qpzaehg0	9	2	,	,	,
cord-263258-qpzaehg0	9	3	5	5	CD
cord-263258-qpzaehg0	10	1	In	in	IN
cord-263258-qpzaehg0	10	2	the	the	DT
cord-263258-qpzaehg0	10	3	first	first	JJ
cord-263258-qpzaehg0	10	4	randomized	randomized	JJ
cord-263258-qpzaehg0	10	5	,	,	,
cord-263258-qpzaehg0	10	6	double	double	JJ
cord-263258-qpzaehg0	10	7	-	-	HYPH
cord-263258-qpzaehg0	10	8	blind	blind	JJ
cord-263258-qpzaehg0	10	9	,	,	,
cord-263258-qpzaehg0	10	10	placebo	placebo	NN
cord-263258-qpzaehg0	10	11	-	-	HYPH
cord-263258-qpzaehg0	10	12	controlled	control	VBN
cord-263258-qpzaehg0	10	13	clinical	clinical	JJ
cord-263258-qpzaehg0	10	14	trial	trial	NN
cord-263258-qpzaehg0	10	15	assessing	assess	VBG
cord-263258-qpzaehg0	10	16	the	the	DT
cord-263258-qpzaehg0	10	17	effect	effect	NN
cord-263258-qpzaehg0	10	18	of	of	IN
cord-263258-qpzaehg0	10	19	intravenous	intravenous	JJ
cord-263258-qpzaehg0	10	20	remdesivir	remdesivir	NNS
cord-263258-qpzaehg0	10	21	in	in	IN
cord-263258-qpzaehg0	10	22	adults	adult	NNS
cord-263258-qpzaehg0	10	23	admitted	admit	VBN
cord-263258-qpzaehg0	10	24	to	to	IN
cord-263258-qpzaehg0	10	25	hospital	hospital	NN
cord-263258-qpzaehg0	10	26	with	with	IN
cord-263258-qpzaehg0	10	27	severe	severe	JJ
cord-263258-qpzaehg0	10	28	COVID-19	covid-19	NN
cord-263258-qpzaehg0	11	1	(	(	-LRB-
cord-263258-qpzaehg0	11	2	n=	n=	NNP
cord-263258-qpzaehg0	11	3	237	237	CD
cord-263258-qpzaehg0	11	4	)	)	-RRB-
cord-263258-qpzaehg0	12	1	a	a	DT
cord-263258-qpzaehg0	12	2	higher	high	JJR
cord-263258-qpzaehg0	12	3	proportion	proportion	NN
cord-263258-qpzaehg0	12	4	of	of	IN
cord-263258-qpzaehg0	12	5	remdesivir	remdesivir	JJ
cord-263258-qpzaehg0	12	6	recipients	recipient	NNS
cord-263258-qpzaehg0	12	7	than	than	IN
cord-263258-qpzaehg0	12	8	placebo	placebo	NN
cord-263258-qpzaehg0	12	9	recipients	recipient	NNS
cord-263258-qpzaehg0	12	10	had	have	VBD
cord-263258-qpzaehg0	12	11	dosing	dose	VBG
cord-263258-qpzaehg0	12	12	prematurely	prematurely	RB
cord-263258-qpzaehg0	12	13	stopped	stop	VBN
cord-263258-qpzaehg0	12	14	by	by	IN
cord-263258-qpzaehg0	12	15	the	the	DT
cord-263258-qpzaehg0	12	16	investigators	investigator	NNS
cord-263258-qpzaehg0	12	17	because	because	IN
cord-263258-qpzaehg0	12	18	of	of	IN
cord-263258-qpzaehg0	12	19	adverse	adverse	JJ
cord-263258-qpzaehg0	12	20	events	event	NNS
cord-263258-qpzaehg0	12	21	including	include	VBG
cord-263258-qpzaehg0	12	22	aminotransferase	aminotransferase	NN
cord-263258-qpzaehg0	12	23	or	or	CC
cord-263258-qpzaehg0	12	24	bilirubin	bilirubin	NN
cord-263258-qpzaehg0	12	25	increases	increase	NNS
cord-263258-qpzaehg0	12	26	(	(	-LRB-
cord-263258-qpzaehg0	12	27	3	3	CD
cord-263258-qpzaehg0	12	28	versus	versus	IN
cord-263258-qpzaehg0	12	29	0	0	CD
cord-263258-qpzaehg0	12	30	)	)	-RRB-
cord-263258-qpzaehg0	12	31	.	.	.
cord-263258-qpzaehg0	13	1	6	6	CD
cord-263258-qpzaehg0	14	1	Although	although	IN
cord-263258-qpzaehg0	14	2	there	there	EX
cord-263258-qpzaehg0	14	3	is	be	VBZ
cord-263258-qpzaehg0	14	4	no	no	DT
cord-263258-qpzaehg0	14	5	signal	signal	NN
cord-263258-qpzaehg0	14	6	from	from	IN
cord-263258-qpzaehg0	14	7	the	the	DT
cord-263258-qpzaehg0	14	8	available	available	JJ
cord-263258-qpzaehg0	14	9	data	datum	NNS
cord-263258-qpzaehg0	14	10	of	of	IN
cord-263258-qpzaehg0	14	11	severe	severe	JJ
cord-263258-qpzaehg0	14	12	hepatotoxicity	hepatotoxicity	NN
cord-263258-qpzaehg0	14	13	or	or	CC
cord-263258-qpzaehg0	14	14	Drug	drug	NN
cord-263258-qpzaehg0	14	15	-	-	HYPH
cord-263258-qpzaehg0	14	16	Induced	Induced	NNP
cord-263258-qpzaehg0	14	17	Liver	Liver	NNP
cord-263258-qpzaehg0	14	18	Injury	injury	NN
cord-263258-qpzaehg0	14	19	(	(	-LRB-
cord-263258-qpzaehg0	14	20	DILI	DILI	NNP
cord-263258-qpzaehg0	14	21	)	)	-RRB-
cord-263258-qpzaehg0	14	22	in	in	IN
cord-263258-qpzaehg0	14	23	clinical	clinical	JJ
cord-263258-qpzaehg0	14	24	trials	trial	NNS
cord-263258-qpzaehg0	14	25	,	,	,
cord-263258-qpzaehg0	14	26	the	the	DT
cord-263258-qpzaehg0	14	27	number	number	NN
cord-263258-qpzaehg0	14	28	of	of	IN
cord-263258-qpzaehg0	14	29	patients	patient	NNS
cord-263258-qpzaehg0	14	30	exposed	expose	VBN
cord-263258-qpzaehg0	14	31	to	to	IN
cord-263258-qpzaehg0	14	32	remdesivir	remdesivir	NNP
cord-263258-qpzaehg0	14	33	was	be	VBD
cord-263258-qpzaehg0	14	34	too	too	RB
cord-263258-qpzaehg0	14	35	limited	limited	JJ
cord-263258-qpzaehg0	14	36	.	.	.
cord-263258-qpzaehg0	15	1	Therefore	therefore	RB
cord-263258-qpzaehg0	15	2	,	,	,
cord-263258-qpzaehg0	15	3	there	there	EX
cord-263258-qpzaehg0	15	4	is	be	VBZ
cord-263258-qpzaehg0	15	5	an	an	DT
cord-263258-qpzaehg0	15	6	urgent	urgent	JJ
cord-263258-qpzaehg0	15	7	need	need	NN
cord-263258-qpzaehg0	15	8	to	to	TO
cord-263258-qpzaehg0	15	9	investigate	investigate	VB
cord-263258-qpzaehg0	15	10	the	the	DT
cord-263258-qpzaehg0	15	11	hepatic	hepatic	JJ
cord-263258-qpzaehg0	15	12	safety	safety	NN
cord-263258-qpzaehg0	15	13	profile	profile	NN
cord-263258-qpzaehg0	15	14	associated	associate	VBN
cord-263258-qpzaehg0	15	15	with	with	IN
cord-263258-qpzaehg0	15	16	remdesivir	remdesivir	NNP
cord-263258-qpzaehg0	15	17	in	in	IN
cord-263258-qpzaehg0	15	18	COVID-19	COVID-19	NNP
cord-263258-qpzaehg0	15	19	patients	patient	NNS
cord-263258-qpzaehg0	15	20	.	.	.
cord-263258-qpzaehg0	16	1	Here	here	RB
cord-263258-qpzaehg0	16	2	,	,	,
cord-263258-qpzaehg0	16	3	we	-PRON-	PRP
cord-263258-qpzaehg0	16	4	performed	perform	VBD
cord-263258-qpzaehg0	16	5	a	a	DT
cord-263258-qpzaehg0	16	6	pharmacovigilance	pharmacovigilance	NN
cord-263258-qpzaehg0	16	7	analysis	analysis	NN
cord-263258-qpzaehg0	16	8	of	of	IN
cord-263258-qpzaehg0	16	9	VigiBase	VigiBase	NNP
cord-263258-qpzaehg0	16	10	,	,	,
cord-263258-qpzaehg0	16	11	the	the	DT
cord-263258-qpzaehg0	16	12	World	World	NNP
cord-263258-qpzaehg0	16	13	Health	Health	NNP
cord-263258-qpzaehg0	16	14	Organization	Organization	NNP
cord-263258-qpzaehg0	16	15	's	's	POS
cord-263258-qpzaehg0	16	16	individual	individual	JJ
cord-263258-qpzaehg0	16	17	case	case	NN
cord-263258-qpzaehg0	16	18	safety	safety	NN
cord-263258-qpzaehg0	16	19	reports	report	NNS
cord-263258-qpzaehg0	16	20	database	database	NN
cord-263258-qpzaehg0	16	21	,	,	,
cord-263258-qpzaehg0	16	22	to	to	TO
cord-263258-qpzaehg0	16	23	describe	describe	VB
cord-263258-qpzaehg0	16	24	hepatic	hepatic	JJ
cord-263258-qpzaehg0	16	25	impairment	impairment	NN
cord-263258-qpzaehg0	16	26	reports	report	NNS
cord-263258-qpzaehg0	16	27	with	with	IN
cord-263258-qpzaehg0	16	28	remdesivir	remdesivir	NNP
cord-263258-qpzaehg0	16	29	.	.	.
cord-263258-qpzaehg0	17	1	7	7	CD
cord-263258-qpzaehg0	17	2	VigiBase	VigiBase	NNP
cord-263258-qpzaehg0	17	3	contains	contain	VBZ
cord-263258-qpzaehg0	17	4	more	more	JJR
cord-263258-qpzaehg0	17	5	than	than	IN
cord-263258-qpzaehg0	17	6	22	22	CD
cord-263258-qpzaehg0	17	7	million	million	CD
cord-263258-qpzaehg0	17	8	spontaneous	spontaneous	JJ
cord-263258-qpzaehg0	17	9	generated	generate	VBD
cord-263258-qpzaehg0	17	10	adverse	adverse	JJ
cord-263258-qpzaehg0	17	11	drug	drug	NN
cord-263258-qpzaehg0	17	12	reactions	reaction	NNS
cord-263258-qpzaehg0	17	13	,	,	,
cord-263258-qpzaehg0	17	14	from	from	IN
cord-263258-qpzaehg0	17	15	136	136	CD
cord-263258-qpzaehg0	17	16	countries	country	NNS
cord-263258-qpzaehg0	17	17	,	,	,
cord-263258-qpzaehg0	17	18	covering	cover	VBG
cord-263258-qpzaehg0	17	19	more	more	JJR
cord-263258-qpzaehg0	17	20	than	than	IN
cord-263258-qpzaehg0	17	21	90	90	CD
cord-263258-qpzaehg0	17	22	%	%	NN
cord-263258-qpzaehg0	17	23	of	of	IN
cord-263258-qpzaehg0	17	24	the	the	DT
cord-263258-qpzaehg0	17	25	world	world	NN
cord-263258-qpzaehg0	17	26	's	's	POS
cord-263258-qpzaehg0	17	27	population	population	NN
cord-263258-qpzaehg0	17	28	.	.	.
cord-263258-qpzaehg0	18	1	VigiBase	VigiBase	NNP
cord-263258-qpzaehg0	18	2	includes	include	VBZ
cord-263258-qpzaehg0	18	3	information	information	NN
cord-263258-qpzaehg0	18	4	on	on	IN
cord-263258-qpzaehg0	18	5	patient	patient	JJ
cord-263258-qpzaehg0	18	6	,	,	,
cord-263258-qpzaehg0	18	7	medical	medical	JJ
cord-263258-qpzaehg0	18	8	history	history	NN
cord-263258-qpzaehg0	18	9	,	,	,
cord-263258-qpzaehg0	18	10	country	country	NN
cord-263258-qpzaehg0	18	11	,	,	,
cord-263258-qpzaehg0	18	12	drugs	drug	NNS
cord-263258-qpzaehg0	18	13	taken	take	VBN
cord-263258-qpzaehg0	18	14	with	with	IN
cord-263258-qpzaehg0	18	15	their	-PRON-	PRP$
cord-263258-qpzaehg0	18	16	initiation	initiation	NN
cord-263258-qpzaehg0	18	17	and	and	CC
cord-263258-qpzaehg0	18	18	stop	stop	VB
cord-263258-qpzaehg0	18	19	date	date	NN
cord-263258-qpzaehg0	18	20	.	.	.
cord-263258-qpzaehg0	19	1	We	-PRON-	PRP
cord-263258-qpzaehg0	19	2	considered	consider	VBD
cord-263258-qpzaehg0	19	3	only	only	RB
cord-263258-qpzaehg0	19	4	reports	report	NNS
cord-263258-qpzaehg0	19	5	of	of	IN
cord-263258-qpzaehg0	19	6	patients	patient	NNS
cord-263258-qpzaehg0	19	7	with	with	IN
cord-263258-qpzaehg0	19	8	COVID-19	COVID-19	NNP
cord-263258-qpzaehg0	19	9	registered	register	VBN
cord-263258-qpzaehg0	19	10	up	up	RP
cord-263258-qpzaehg0	19	11	to	to	IN
cord-263258-qpzaehg0	19	12	the	the	DT
cord-263258-qpzaehg0	19	13	15	15	CD
cord-263258-qpzaehg0	19	14	th	th	CD
cord-263258-qpzaehg0	19	15	of	of	IN
cord-263258-qpzaehg0	19	16	June	June	NNP
cord-263258-qpzaehg0	19	17	2020	2020	CD
cord-263258-qpzaehg0	19	18	.	.	.
cord-263258-qpzaehg0	20	1	Disproportionality	Disproportionality	NNP
cord-263258-qpzaehg0	20	2	analysis	analysis	NN
cord-263258-qpzaehg0	20	3	was	be	VBD
cord-263258-qpzaehg0	20	4	performed	perform	VBN
cord-263258-qpzaehg0	20	5	to	to	TO
cord-263258-qpzaehg0	20	6	assess	assess	VB
cord-263258-qpzaehg0	20	7	a	a	DT
cord-263258-qpzaehg0	20	8	potential	potential	JJ
cord-263258-qpzaehg0	20	9	increased	increase	VBN
cord-263258-qpzaehg0	20	10	risk	risk	NN
cord-263258-qpzaehg0	20	11	of	of	IN
cord-263258-qpzaehg0	20	12	reporting	report	VBG
cord-263258-qpzaehg0	20	13	hepatic	hepatic	JJ
cord-263258-qpzaehg0	20	14	disorders	disorder	NNS
cord-263258-qpzaehg0	20	15	with	with	IN
cord-263258-qpzaehg0	20	16	remdesivir	remdesivir	NNS
cord-263258-qpzaehg0	20	17	compared	compare	VBN
cord-263258-qpzaehg0	20	18	to	to	IN
cord-263258-qpzaehg0	20	19	drugs	drug	NNS
cord-263258-qpzaehg0	20	20	prescribed	prescribe	VBN
cord-263258-qpzaehg0	20	21	in	in	IN
cord-263258-qpzaehg0	20	22	COVID-19	COVID-19	NNP
cord-263258-qpzaehg0	20	23	patients	patient	NNS
cord-263258-qpzaehg0	20	24	.	.	.
cord-263258-qpzaehg0	21	1	8	8	CD
cord-263258-qpzaehg0	22	1	The	the	DT
cord-263258-qpzaehg0	22	2	risk	risk	NN
cord-263258-qpzaehg0	22	3	of	of	IN
cord-263258-qpzaehg0	22	4	hepatic	hepatic	JJ
cord-263258-qpzaehg0	22	5	disorders	disorder	NNS
cord-263258-qpzaehg0	22	6	was	be	VBD
cord-263258-qpzaehg0	22	7	calculated	calculate	VBN
cord-263258-qpzaehg0	22	8	using	use	VBG
cord-263258-qpzaehg0	22	9	the	the	DT
cord-263258-qpzaehg0	22	10	Reporting	Reporting	NNP
cord-263258-qpzaehg0	22	11	Odds	Odds	NNPS
cord-263258-qpzaehg0	22	12	Ratios	Ratios	NNP
cord-263258-qpzaehg0	22	13	(	(	-LRB-
cord-263258-qpzaehg0	22	14	ROR	ROR	NNP
cord-263258-qpzaehg0	22	15	)	)	-RRB-
cord-263258-qpzaehg0	22	16	with	with	IN
cord-263258-qpzaehg0	22	17	their	-PRON-	PRP$
cord-263258-qpzaehg0	22	18	95	95	CD
cord-263258-qpzaehg0	22	19	%	%	NN
cord-263258-qpzaehg0	22	20	confidence	confidence	NN
cord-263258-qpzaehg0	22	21	interval	interval	NN
cord-263258-qpzaehg0	22	22	(	(	-LRB-
cord-263258-qpzaehg0	22	23	CI	CI	NNP
cord-263258-qpzaehg0	22	24	)	)	-RRB-
cord-263258-qpzaehg0	22	25	,	,	,
cord-263258-qpzaehg0	22	26	a	a	DT
cord-263258-qpzaehg0	22	27	ratio	ratio	NN
cord-263258-qpzaehg0	22	28	similar	similar	JJ
cord-263258-qpzaehg0	22	29	in	in	IN
cord-263258-qpzaehg0	22	30	concept	concept	NN
cord-263258-qpzaehg0	22	31	to	to	IN
cord-263258-qpzaehg0	22	32	the	the	DT
cord-263258-qpzaehg0	22	33	Odds	Odds	NNPS
cord-263258-qpzaehg0	22	34	Ratio	Ratio	NNP
cord-263258-qpzaehg0	22	35	in	in	IN
cord-263258-qpzaehg0	22	36	case	case	NN
cord-263258-qpzaehg0	22	37	-	-	HYPH
cord-263258-qpzaehg0	22	38	control	control	NN
cord-263258-qpzaehg0	22	39	studies	study	NNS
cord-263258-qpzaehg0	22	40	..	..	.
cord-263258-qpzaehg0	23	1	To	to	TO
cord-263258-qpzaehg0	23	2	minimize	minimize	VB
cord-263258-qpzaehg0	23	3	the	the	DT
cord-263258-qpzaehg0	23	4	potential	potential	NN
cord-263258-qpzaehg0	23	5	of	of	IN
cord-263258-qpzaehg0	23	6	confounding	confound	VBG
cord-263258-qpzaehg0	23	7	by	by	IN
cord-263258-qpzaehg0	23	8	disease	disease	NN
cord-263258-qpzaehg0	23	9	severity	severity	NN
cord-263258-qpzaehg0	23	10	(	(	-LRB-
cord-263258-qpzaehg0	23	11	hepatic	hepatic	JJ
cord-263258-qpzaehg0	23	12	disorders	disorder	NNS
cord-263258-qpzaehg0	23	13	could	could	MD
cord-263258-qpzaehg0	23	14	be	be	VB
cord-263258-qpzaehg0	23	15	associated	associate	VBN
cord-263258-qpzaehg0	23	16	with	with	IN
cord-263258-qpzaehg0	23	17	the	the	DT
cord-263258-qpzaehg0	23	18	severity	severity	NN
cord-263258-qpzaehg0	23	19	of	of	IN
cord-263258-qpzaehg0	23	20	COVID-19	covid-19	JJ
cord-263258-qpzaehg0	23	21	infection	infection	NN
cord-263258-qpzaehg0	23	22	)	)	-RRB-
cord-263258-qpzaehg0	23	23	,	,	,
cord-263258-qpzaehg0	23	24	we	-PRON-	PRP
cord-263258-qpzaehg0	23	25	repeated	repeat	VBD
cord-263258-qpzaehg0	23	26	the	the	DT
cord-263258-qpzaehg0	23	27	primary	primary	JJ
cord-263258-qpzaehg0	23	28	analysis	analysis	NN
cord-263258-qpzaehg0	23	29	considering	consider	VBG
cord-263258-qpzaehg0	23	30	only	only	RB
cord-263258-qpzaehg0	23	31	users	user	NNS
cord-263258-qpzaehg0	23	32	of	of	IN
cord-263258-qpzaehg0	23	33	tocilizumab	tocilizumab	NNP
cord-263258-qpzaehg0	23	34	,	,	,
cord-263258-qpzaehg0	23	35	a	a	DT
cord-263258-qpzaehg0	23	36	drug	drug	NN
cord-263258-qpzaehg0	23	37	recommended	recommend	VBN
cord-263258-qpzaehg0	23	38	in	in	IN
cord-263258-qpzaehg0	23	39	severe	severe	JJ
cord-263258-qpzaehg0	23	40	COVID-19	covid-19	JJ
cord-263258-qpzaehg0	23	41	cases	case	NNS
cord-263258-qpzaehg0	23	42	.	.	.
cord-263258-qpzaehg0	24	1	We	-PRON-	PRP
cord-263258-qpzaehg0	24	2	found	find	VBD
cord-263258-qpzaehg0	24	3	387	387	CD
cord-263258-qpzaehg0	24	4	reports	report	NNS
cord-263258-qpzaehg0	24	5	with	with	IN
cord-263258-qpzaehg0	24	6	remdesivir	remdesivir	NNP
cord-263258-qpzaehg0	24	7	registered	register	VBN
cord-263258-qpzaehg0	24	8	in	in	IN
cord-263258-qpzaehg0	24	9	VigiBase	VigiBase	NNP
cord-263258-qpzaehg0	24	10	,	,	,
cord-263258-qpzaehg0	24	11	and	and	CC
cord-263258-qpzaehg0	24	12	among	among	IN
cord-263258-qpzaehg0	24	13	them	-PRON-	PRP
cord-263258-qpzaehg0	24	14	130	130	CD
cord-263258-qpzaehg0	24	15	hepatic	hepatic	JJ
cord-263258-qpzaehg0	24	16	adverse	adverse	JJ
cord-263258-qpzaehg0	24	17	effects	effect	NNS
cord-263258-qpzaehg0	24	18	were	be	VBD
cord-263258-qpzaehg0	24	19	reported	report	VBN
cord-263258-qpzaehg0	24	20	(	(	-LRB-
cord-263258-qpzaehg0	24	21	34	34	CD
cord-263258-qpzaehg0	24	22	%	%	NN
cord-263258-qpzaehg0	24	23	)	)	-RRB-
cord-263258-qpzaehg0	24	24	.	.	.
cord-263258-qpzaehg0	25	1	Reports	report	NNS
cord-263258-qpzaehg0	25	2	originated	originate	VBD
cord-263258-qpzaehg0	25	3	from	from	IN
cord-263258-qpzaehg0	25	4	US	US	NNP
cord-263258-qpzaehg0	25	5	(	(	-LRB-
cord-263258-qpzaehg0	25	6	87	87	CD
cord-263258-qpzaehg0	25	7	)	)	-RRB-
cord-263258-qpzaehg0	25	8	and	and	CC
cord-263258-qpzaehg0	25	9	Europe	Europe	NNP
cord-263258-qpzaehg0	25	10	(	(	-LRB-
cord-263258-qpzaehg0	25	11	43	43	CD
cord-263258-qpzaehg0	25	12	)	)	-RRB-
cord-263258-qpzaehg0	25	13	,	,	,
cord-263258-qpzaehg0	25	14	involving	involve	VBG
cord-263258-qpzaehg0	25	15	mostly	mostly	RB
cord-263258-qpzaehg0	25	16	men	man	NNS
cord-263258-qpzaehg0	25	17	(	(	-LRB-
cord-263258-qpzaehg0	25	18	81	81	CD
cord-263258-qpzaehg0	25	19	,	,	,
cord-263258-qpzaehg0	25	20	62	62	CD
cord-263258-qpzaehg0	25	21	%	%	NN
cord-263258-qpzaehg0	25	22	)	)	-RRB-
cord-263258-qpzaehg0	25	23	,	,	,
cord-263258-qpzaehg0	25	24	with	with	IN
cord-263258-qpzaehg0	25	25	a	a	DT
cord-263258-qpzaehg0	25	26	mean	mean	JJ
cord-263258-qpzaehg0	25	27	age	age	NN
cord-263258-qpzaehg0	25	28	of	of	IN
cord-263258-qpzaehg0	25	29	54·9	54·9	CD
cord-263258-qpzaehg0	25	30	years	year	NNS
cord-263258-qpzaehg0	25	31	(	(	-LRB-
cord-263258-qpzaehg0	25	32	min	min	NNP
cord-263258-qpzaehg0	25	33	2	2	CD
cord-263258-qpzaehg0	25	34	,	,	,
cord-263258-qpzaehg0	25	35	max	max	NNP
cord-263258-qpzaehg0	25	36	92	92	CD
cord-263258-qpzaehg0	25	37	)	)	-RRB-
cord-263258-qpzaehg0	25	38	.	.	.
cord-263258-qpzaehg0	26	1	Treatment	treatment	NN
cord-263258-qpzaehg0	26	2	duration	duration	NN
cord-263258-qpzaehg0	26	3	with	with	IN
cord-263258-qpzaehg0	26	4	remdesivir	remdesivir	NNP
cord-263258-qpzaehg0	26	5	varied	vary	VBN
cord-263258-qpzaehg0	26	6	between	between	IN
cord-263258-qpzaehg0	26	7	1	1	CD
cord-263258-qpzaehg0	26	8	day	day	NN
cord-263258-qpzaehg0	26	9	(	(	-LRB-
cord-263258-qpzaehg0	26	10	15	15	CD
cord-263258-qpzaehg0	26	11	discontinuations	discontinuation	NNS
cord-263258-qpzaehg0	26	12	for	for	IN
cord-263258-qpzaehg0	26	13	serious	serious	JJ
cord-263258-qpzaehg0	26	14	adverse	adverse	JJ
cord-263258-qpzaehg0	26	15	effects	effect	NNS
cord-263258-qpzaehg0	26	16	)	)	-RRB-
cord-263258-qpzaehg0	26	17	and	and	CC
cord-263258-qpzaehg0	26	18	11	11	CD
cord-263258-qpzaehg0	26	19	days	day	NNS
cord-263258-qpzaehg0	26	20	,	,	,
cord-263258-qpzaehg0	26	21	with	with	IN
cord-263258-qpzaehg0	26	22	a	a	DT
cord-263258-qpzaehg0	26	23	mean	mean	JJ
cord-263258-qpzaehg0	26	24	duration	duration	NN
cord-263258-qpzaehg0	26	25	of	of	IN
cord-263258-qpzaehg0	26	26	3.8	3.8	CD
cord-263258-qpzaehg0	26	27	days	day	NNS
cord-263258-qpzaehg0	26	28	.	.	.
cord-263258-qpzaehg0	27	1	In	in	IN
cord-263258-qpzaehg0	27	2	the	the	DT
cord-263258-qpzaehg0	27	3	majority	majority	NN
cord-263258-qpzaehg0	27	4	of	of	IN
cord-263258-qpzaehg0	27	5	cases	case	NNS
cord-263258-qpzaehg0	27	6	(	(	-LRB-
cord-263258-qpzaehg0	27	7	122	122	CD
cord-263258-qpzaehg0	27	8	,	,	,
cord-263258-qpzaehg0	27	9	94	94	CD
cord-263258-qpzaehg0	27	10	%	%	NN
cord-263258-qpzaehg0	27	11	)	)	-RRB-
cord-263258-qpzaehg0	27	12	,	,	,
cord-263258-qpzaehg0	27	13	remdesivir	remdesivir	NNP
cord-263258-qpzaehg0	27	14	was	be	VBD
cord-263258-qpzaehg0	27	15	the	the	DT
cord-263258-qpzaehg0	27	16	sole	sole	JJ
cord-263258-qpzaehg0	27	17	suspected	suspect	VBN
cord-263258-qpzaehg0	27	18	drug	drug	NN
cord-263258-qpzaehg0	27	19	.	.	.
cord-263258-qpzaehg0	28	1	Most	Most	JJS
cord-263258-qpzaehg0	28	2	of	of	IN
cord-263258-qpzaehg0	28	3	cases	case	NNS
cord-263258-qpzaehg0	28	4	were	be	VBD
cord-263258-qpzaehg0	28	5	serious	serious	JJ
cord-263258-qpzaehg0	28	6	(	(	-LRB-
cord-263258-qpzaehg0	28	7	94	94	CD
cord-263258-qpzaehg0	28	8	,	,	,
cord-263258-qpzaehg0	28	9	72	72	CD
cord-263258-qpzaehg0	28	10	%	%	NN
cord-263258-qpzaehg0	28	11	)	)	-RRB-
cord-263258-qpzaehg0	28	12	(	(	-LRB-
cord-263258-qpzaehg0	28	13	i.e.	i.e.	FW
cord-263258-qpzaehg0	28	14	resulting	result	VBG
cord-263258-qpzaehg0	28	15	in	in	IN
cord-263258-qpzaehg0	28	16	hospitalization	hospitalization	NN
cord-263258-qpzaehg0	28	17	or	or	CC
cord-263258-qpzaehg0	28	18	prolongation	prolongation	NN
cord-263258-qpzaehg0	28	19	of	of	IN
cord-263258-qpzaehg0	28	20	hospital	hospital	NN
cord-263258-qpzaehg0	28	21	stay	stay	NN
cord-263258-qpzaehg0	28	22	)	)	-RRB-
cord-263258-qpzaehg0	28	23	.	.	.
cord-263258-qpzaehg0	29	1	The	the	DT
cord-263258-qpzaehg0	29	2	mean	mean	JJ
cord-263258-qpzaehg0	29	3	time	time	NN
cord-263258-qpzaehg0	29	4	to	to	IN
cord-263258-qpzaehg0	29	5	onset	onset	VB
cord-263258-qpzaehg0	29	6	hepatic	hepatic	JJ
cord-263258-qpzaehg0	29	7	disorders	disorder	NNS
cord-263258-qpzaehg0	29	8	was	be	VBD
cord-263258-qpzaehg0	29	9	5.4	5.4	CD
cord-263258-qpzaehg0	29	10	days	day	NNS
cord-263258-qpzaehg0	29	11	.	.	.
cord-263258-qpzaehg0	30	1	Hepatic	hepatic	JJ
cord-263258-qpzaehg0	30	2	enzymes	enzyme	NNS
cord-263258-qpzaehg0	30	3	increased	increase	VBD
cord-263258-qpzaehg0	30	4	were	be	VBD
cord-263258-qpzaehg0	30	5	the	the	DT
cord-263258-qpzaehg0	30	6	most	most	RBS
cord-263258-qpzaehg0	30	7	frequent	frequent	JJ
cord-263258-qpzaehg0	30	8	adverse	adverse	JJ
cord-263258-qpzaehg0	30	9	drug	drug	NN
cord-263258-qpzaehg0	30	10	reactions	reaction	NNS
cord-263258-qpzaehg0	30	11	reported	report	VBN
cord-263258-qpzaehg0	30	12	(	(	-LRB-
cord-263258-qpzaehg0	30	13	114	114	CD
cord-263258-qpzaehg0	30	14	,	,	,
cord-263258-qpzaehg0	30	15	88	88	CD
cord-263258-qpzaehg0	30	16	%	%	NN
cord-263258-qpzaehg0	30	17	)	)	-RRB-
cord-263258-qpzaehg0	30	18	involving	involve	VBG
cord-263258-qpzaehg0	30	19	the	the	DT
cord-263258-qpzaehg0	30	20	liver	liver	NN
cord-263258-qpzaehg0	30	21	transaminases	transaminase	NNS
cord-263258-qpzaehg0	30	22	(	(	-LRB-
cord-263258-qpzaehg0	30	23	aspartate	aspartate	NN
cord-263258-qpzaehg0	30	24	transaminase	transaminase	NN
cord-263258-qpzaehg0	30	25	and	and	CC
cord-263258-qpzaehg0	30	26	alanine	alanine	NN
cord-263258-qpzaehg0	30	27	transaminase	transaminase	FW
cord-263258-qpzaehg0	30	28	)	)	-RRB-
cord-263258-qpzaehg0	30	29	in	in	IN
cord-263258-qpzaehg0	30	30	79	79	CD
cord-263258-qpzaehg0	30	31	cases	case	NNS
cord-263258-qpzaehg0	30	32	(	(	-LRB-
cord-263258-qpzaehg0	30	33	61	61	CD
cord-263258-qpzaehg0	30	34	%	%	NN
cord-263258-qpzaehg0	30	35	)	)	-RRB-
cord-263258-qpzaehg0	30	36	and	and	CC
cord-263258-qpzaehg0	30	37	bilirubin	bilirubin	NN
cord-263258-qpzaehg0	30	38	in	in	IN
cord-263258-qpzaehg0	30	39	4	4	CD
cord-263258-qpzaehg0	30	40	cases	case	NNS
cord-263258-qpzaehg0	30	41	(	(	-LRB-
cord-263258-qpzaehg0	30	42	3	3	CD
cord-263258-qpzaehg0	30	43	%	%	NN
cord-263258-qpzaehg0	30	44	)	)	-RRB-
cord-263258-qpzaehg0	30	45	.	.	.
cord-263258-qpzaehg0	31	1	Other	other	JJ
cord-263258-qpzaehg0	31	2	cases	case	NNS
cord-263258-qpzaehg0	31	3	were	be	VBD
cord-263258-qpzaehg0	31	4	reported	report	VBN
cord-263258-qpzaehg0	31	5	as	as	IN
cord-263258-qpzaehg0	31	6	hepatic	hepatic	JJ
cord-263258-qpzaehg0	31	7	failure	failure	NN
cord-263258-qpzaehg0	31	8	or	or	CC
cord-263258-qpzaehg0	31	9	hepatitis	hepatitis	NN
cord-263258-qpzaehg0	31	10	.	.	.
cord-263258-qpzaehg0	32	1	Compared	compare	VBN
cord-263258-qpzaehg0	32	2	with	with	IN
cord-263258-qpzaehg0	32	3	hydroxychloroquine	hydroxychloroquine	NNP
cord-263258-qpzaehg0	32	4	,	,	,
cord-263258-qpzaehg0	32	5	lopinavir	lopinavir	NNP
cord-263258-qpzaehg0	32	6	/	/	SYM
cord-263258-qpzaehg0	32	7	ritonavir	ritonavir	NNP
cord-263258-qpzaehg0	32	8	or	or	CC
cord-263258-qpzaehg0	32	9	tocilizumab	tocilizumab	NNP
cord-263258-qpzaehg0	32	10	,	,	,
cord-263258-qpzaehg0	32	11	the	the	DT
cord-263258-qpzaehg0	32	12	use	use	NN
cord-263258-qpzaehg0	32	13	of	of	IN
cord-263258-qpzaehg0	32	14	remdesivir	remdesivir	NNP
cord-263258-qpzaehg0	32	15	was	be	VBD
cord-263258-qpzaehg0	32	16	associated	associate	VBN
cord-263258-qpzaehg0	32	17	with	with	IN
cord-263258-qpzaehg0	32	18	an	an	DT
cord-263258-qpzaehg0	32	19	increased	increase	VBN
cord-263258-qpzaehg0	32	20	risk	risk	NN
cord-263258-qpzaehg0	32	21	of	of	IN
cord-263258-qpzaehg0	32	22	reporting	report	VBG
cord-263258-qpzaehg0	32	23	hepatic	hepatic	JJ
cord-263258-qpzaehg0	32	24	disorders	disorder	NNS
cord-263258-qpzaehg0	32	25	(	(	-LRB-
cord-263258-qpzaehg0	32	26	ROR	ROR	NNP
cord-263258-qpzaehg0	32	27	1.94	1.94	CD
cord-263258-qpzaehg0	32	28	;	;	:
cord-263258-qpzaehg0	32	29	95	95	CD
cord-263258-qpzaehg0	32	30	%	%	NN
cord-263258-qpzaehg0	32	31	7	7	CD
cord-263258-qpzaehg0	32	32	Abbreviations	abbreviation	NNS
cord-263258-qpzaehg0	32	33	:	:	:
cord-263258-qpzaehg0	32	34	CI	CI	NNP
cord-263258-qpzaehg0	32	35	,	,	,
cord-263258-qpzaehg0	32	36	confidence	confidence	NN
cord-263258-qpzaehg0	32	37	interval	interval	NN
cord-263258-qpzaehg0	32	38	;	;	:
cord-263258-qpzaehg0	32	39	COVID-19	COVID-19	NNP
cord-263258-qpzaehg0	32	40	,	,	,
cord-263258-qpzaehg0	32	41	coronavirus	coronavirus	NN
cord-263258-qpzaehg0	32	42	disease	disease	NN
cord-263258-qpzaehg0	32	43	2019	2019	CD
cord-263258-qpzaehg0	32	44	;	;	:
cord-263258-qpzaehg0	32	45	ROR	ROR	NNP
cord-263258-qpzaehg0	32	46	,	,	,
cord-263258-qpzaehg0	32	47	reporting	report	VBG
cord-263258-qpzaehg0	32	48	odds	odd	NNS
cord-263258-qpzaehg0	32	49	ratio	ratio	NN
cord-263258-qpzaehg0	32	50	.	.	.
cord-263258-qpzaehg0	33	1	a	a	DT
cord-263258-qpzaehg0	33	2	We	-PRON-	PRP
cord-263258-qpzaehg0	33	3	used	use	VBD
cord-263258-qpzaehg0	33	4	the	the	DT
cord-263258-qpzaehg0	33	5	case	case	NN
cord-263258-qpzaehg0	33	6	non	non	JJ
cord-263258-qpzaehg0	33	7	-	-	JJ
cord-263258-qpzaehg0	33	8	case	case	JJ
cord-263258-qpzaehg0	33	9	method	method	NN
cord-263258-qpzaehg0	33	10	which	which	WDT
cord-263258-qpzaehg0	33	11	is	be	VBZ
cord-263258-qpzaehg0	33	12	similar	similar	JJ
cord-263258-qpzaehg0	33	13	to	to	IN
cord-263258-qpzaehg0	33	14	case	case	NN
cord-263258-qpzaehg0	33	15	-	-	HYPH
cord-263258-qpzaehg0	33	16	control	control	NN
cord-263258-qpzaehg0	33	17	studies	study	NNS
cord-263258-qpzaehg0	33	18	but	but	CC
cord-263258-qpzaehg0	33	19	adapted	adapt	VBN
cord-263258-qpzaehg0	33	20	for	for	IN
cord-263258-qpzaehg0	33	21	pharmacovigilance	pharmacovigilance	NN
cord-263258-qpzaehg0	33	22	studies	study	NNS
cord-263258-qpzaehg0	33	23	.	.	.
cord-263258-qpzaehg0	34	1	We	-PRON-	PRP
cord-263258-qpzaehg0	34	2	used	use	VBD
cord-263258-qpzaehg0	34	3	reporting	report	VBG
cord-263258-qpzaehg0	34	4	odds	odd	NNS
cord-263258-qpzaehg0	34	5	ratios	ratio	NNS
cord-263258-qpzaehg0	34	6	(	(	-LRB-
cord-263258-qpzaehg0	34	7	ROR	ROR	NNP
cord-263258-qpzaehg0	34	8	)	)	-RRB-
cord-263258-qpzaehg0	34	9	and	and	CC
cord-263258-qpzaehg0	34	10	their	-PRON-	PRP$
cord-263258-qpzaehg0	34	11	95	95	CD
cord-263258-qpzaehg0	34	12	%	%	NN
cord-263258-qpzaehg0	34	13	confidence	confidence	NN
cord-263258-qpzaehg0	34	14	interval	interval	NN
cord-263258-qpzaehg0	34	15	(	(	-LRB-
cord-263258-qpzaehg0	34	16	95	95	CD
cord-263258-qpzaehg0	34	17	%	%	NN
cord-263258-qpzaehg0	34	18	CI	CI	NNP
cord-263258-qpzaehg0	34	19	)	)	-RRB-
cord-263258-qpzaehg0	34	20	to	to	TO
cord-263258-qpzaehg0	34	21	calculate	calculate	VB
cord-263258-qpzaehg0	34	22	disproportionality	disproportionality	NN
cord-263258-qpzaehg0	34	23	.	.	.
cord-263258-qpzaehg0	35	1	ROR	ROR	NNP
cord-263258-qpzaehg0	35	2	is	be	VBZ
cord-263258-qpzaehg0	35	3	a	a	DT
cord-263258-qpzaehg0	35	4	ratio	ratio	NN
cord-263258-qpzaehg0	35	5	similar	similar	JJ
cord-263258-qpzaehg0	35	6	in	in	IN
cord-263258-qpzaehg0	35	7	concept	concept	NN
cord-263258-qpzaehg0	35	8	to	to	IN
cord-263258-qpzaehg0	35	9	the	the	DT
cord-263258-qpzaehg0	35	10	odds	odd	NNS
cord-263258-qpzaehg0	35	11	ratio	ratio	NN
cord-263258-qpzaehg0	35	12	in	in	IN
cord-263258-qpzaehg0	35	13	case	case	NN
cord-263258-qpzaehg0	35	14	-	-	HYPH
cord-263258-qpzaehg0	35	15	control	control	NN
cord-263258-qpzaehg0	35	16	studies	study	NNS
cord-263258-qpzaehg0	35	17	and	and	CC
cord-263258-qpzaehg0	35	18	corresponds	correspond	VBZ
cord-263258-qpzaehg0	35	19	to	to	IN
cord-263258-qpzaehg0	35	20	the	the	DT
cord-263258-qpzaehg0	35	21	exposure	exposure	NN
cord-263258-qpzaehg0	35	22	odds	odd	NNS
cord-263258-qpzaehg0	35	23	among	among	IN
cord-263258-qpzaehg0	35	24	reported	report	VBN
cord-263258-qpzaehg0	35	25	cases	case	NNS
cord-263258-qpzaehg0	35	26	of	of	IN
cord-263258-qpzaehg0	35	27	hepatic	hepatic	JJ
cord-263258-qpzaehg0	35	28	disorders	disorder	NNS
cord-263258-qpzaehg0	35	29	over	over	IN
cord-263258-qpzaehg0	35	30	the	the	DT
cord-263258-qpzaehg0	35	31	exposure	exposure	NN
cord-263258-qpzaehg0	35	32	odds	odd	NNS
cord-263258-qpzaehg0	35	33	among	among	IN
cord-263258-qpzaehg0	35	34	reported	report	VBN
cord-263258-qpzaehg0	35	35	non	non	JJ
cord-263258-qpzaehg0	35	36	-	-	NN
cord-263258-qpzaehg0	35	37	case	case	NN
cord-263258-qpzaehg0	35	38	b	b	NN
cord-263258-qpzaehg0	35	39	Cases	case	NNS
cord-263258-qpzaehg0	36	1	were	be	VBD
cord-263258-qpzaehg0	36	2	individual	individual	JJ
cord-263258-qpzaehg0	36	3	case	case	NN
cord-263258-qpzaehg0	36	4	safety	safety	NN
cord-263258-qpzaehg0	36	5	reports	report	NNS
cord-263258-qpzaehg0	36	6	containing	contain	VBG
cord-263258-qpzaehg0	36	7	any	any	DT
cord-263258-qpzaehg0	36	8	terms	term	NNS
cord-263258-qpzaehg0	36	9	including	include	VBG
cord-263258-qpzaehg0	36	10	the	the	DT
cord-263258-qpzaehg0	36	11	terminology	terminology	NN
cord-263258-qpzaehg0	36	12	"	"	``
cord-263258-qpzaehg0	36	13	Hepatobiliary	Hepatobiliary	NNP
cord-263258-qpzaehg0	36	14	disorders	disorder	NNS
cord-263258-qpzaehg0	36	15	"	"	''
cord-263258-qpzaehg0	36	16	in	in	IN
cord-263258-qpzaehg0	36	17	the	the	DT
cord-263258-qpzaehg0	36	18	System	System	NNP
cord-263258-qpzaehg0	36	19	Organ	Organ	NNP
cord-263258-qpzaehg0	36	20	Class	Class	NNP
cord-263258-qpzaehg0	36	21	(	(	-LRB-
cord-263258-qpzaehg0	36	22	SOC	SOC	NNP
cord-263258-qpzaehg0	36	23	)	)	-RRB-
cord-263258-qpzaehg0	36	24	view	view	NN
cord-263258-qpzaehg0	36	25	found	find	VBN
cord-263258-qpzaehg0	36	26	in	in	IN
cord-263258-qpzaehg0	36	27	MedDRA	MedDRA	NNP
cord-263258-qpzaehg0	36	28	dictionary	dictionary	NNP
cord-263258-qpzaehg0	36	29	https://www.meddra.org/	https://www.meddra.org/	NNP
cord-263258-qpzaehg0	36	30	.	.	.
cord-263258-qpzaehg0	37	1	c	c	LS
cord-263258-qpzaehg0	37	2	Non	Non	NNS
cord-263258-qpzaehg0	37	3	-	-	NNS
cord-263258-qpzaehg0	37	4	cases	case	NNS
cord-263258-qpzaehg0	37	5	were	be	VBD
cord-263258-qpzaehg0	37	6	individual	individual	JJ
cord-263258-qpzaehg0	37	7	case	case	NN
cord-263258-qpzaehg0	37	8	safety	safety	NN
cord-263258-qpzaehg0	37	9	reports	report	NNS
cord-263258-qpzaehg0	37	10	containing	contain	VBG
cord-263258-qpzaehg0	37	11	all	all	DT
cord-263258-qpzaehg0	37	12	other	other	JJ
cord-263258-qpzaehg0	37	13	adverse	adverse	JJ
cord-263258-qpzaehg0	37	14	events	event	NNS
cord-263258-qpzaehg0	37	15	reported	report	VBD
cord-263258-qpzaehg0	37	16	linked	link	VBN
cord-263258-qpzaehg0	37	17	with	with	IN
cord-263258-qpzaehg0	37	18	the	the	DT
cord-263258-qpzaehg0	37	19	respective	respective	JJ
cord-263258-qpzaehg0	37	20	drug	drug	NN
cord-263258-qpzaehg0	37	21	.	.	.
cord-263258-qpzaehg0	38	1	d	d	NNP
cord-263258-qpzaehg0	38	2	hydroxychloroquine	hydroxychloroquine	NNP
cord-263258-qpzaehg0	38	3	,	,	,
cord-263258-qpzaehg0	38	4	tocilizumab	tocilizumab	NNP
cord-263258-qpzaehg0	38	5	,	,	,
cord-263258-qpzaehg0	38	6	lopinavir	lopinavir	NNP
cord-263258-qpzaehg0	38	7	/	/	SYM
cord-263258-qpzaehg0	38	8	ritonavir	ritonavir	NNP
cord-263258-qpzaehg0	38	9	prescribed	prescribe	VBN
cord-263258-qpzaehg0	38	10	for	for	IN
cord-263258-qpzaehg0	38	11	COVID-19	COVID-19	NNP
cord-263258-qpzaehg0	38	12	patients	patient	NNS
cord-263258-qpzaehg0	38	13	 	 	_SP
cord-263258-qpzaehg0	39	1	COVID-19	covid-19	LS
cord-263258-qpzaehg0	39	2	)	)	-RRB-
cord-263258-qpzaehg0	39	3	Update	update	NN
cord-263258-qpzaehg0	39	4	:	:	:
cord-263258-qpzaehg0	40	1	FDA	FDA	NNP
cord-263258-qpzaehg0	40	2	Issues	Issues	NNPS
cord-263258-qpzaehg0	40	3	Emergency	Emergency	NNP
cord-263258-qpzaehg0	40	4	Use	Use	NNP
cord-263258-qpzaehg0	40	5	Authorization	Authorization	NNP
cord-263258-qpzaehg0	40	6	for	for	IN
cord-263258-qpzaehg0	40	7	Potential	Potential	NNP
cord-263258-qpzaehg0	40	8	COVID-19	COVID-19	NNP
cord-263258-qpzaehg0	40	9	Treatment	Treatment	NNP
cord-263258-qpzaehg0	40	10	First	First	NNP
cord-263258-qpzaehg0	41	1	COVID-19	covid-19	JJ
cord-263258-qpzaehg0	41	2	treatment	treatment	NN
cord-263258-qpzaehg0	41	3	recommended	recommend	VBN
cord-263258-qpzaehg0	41	4	for	for	IN
cord-263258-qpzaehg0	41	5	EU	EU	NNP
cord-263258-qpzaehg0	41	6	authorisation	authorisation	NN
cord-263258-qpzaehg0	41	7	Remdesivir	Remdesivir	NNP
cord-263258-qpzaehg0	41	8	for	for	IN
cord-263258-qpzaehg0	41	9	5	5	CD
cord-263258-qpzaehg0	41	10	or	or	CC
cord-263258-qpzaehg0	41	11	10	10	CD
cord-263258-qpzaehg0	41	12	Days	day	NNS
cord-263258-qpzaehg0	41	13	in	in	IN
cord-263258-qpzaehg0	41	14	Patients	patient	NNS
cord-263258-qpzaehg0	41	15	with	with	IN
cord-263258-qpzaehg0	41	16	Severe	severe	JJ
cord-263258-qpzaehg0	41	17	Covid-19	covid-19	JJ
cord-263258-qpzaehg0	41	18	Compassionate	compassionate	JJ
cord-263258-qpzaehg0	41	19	remdesivir	remdesivir	JJ
cord-263258-qpzaehg0	41	20	treatment	treatment	NN
cord-263258-qpzaehg0	41	21	of	of	IN
cord-263258-qpzaehg0	41	22	severe	severe	JJ
cord-263258-qpzaehg0	41	23	Covid-19	covid-19	JJ
cord-263258-qpzaehg0	41	24	pneumonia	pneumonia	NN
cord-263258-qpzaehg0	41	25	in	in	IN
cord-263258-qpzaehg0	41	26	intensive	intensive	JJ
cord-263258-qpzaehg0	41	27	care	care	NN
cord-263258-qpzaehg0	41	28	unit	unit	NN
cord-263258-qpzaehg0	41	29	(	(	-LRB-
cord-263258-qpzaehg0	41	30	ICU	ICU	NNP
cord-263258-qpzaehg0	41	31	)	)	-RRB-
cord-263258-qpzaehg0	41	32	and	and	CC
cord-263258-qpzaehg0	41	33	Non	Non	NNP
cord-263258-qpzaehg0	41	34	-	-	JJ
cord-263258-qpzaehg0	41	35	ICU	icu	JJ
cord-263258-qpzaehg0	41	36	patients	patient	NNS
cord-263258-qpzaehg0	41	37	:	:	:
cord-263258-qpzaehg0	41	38	Clinical	clinical	JJ
cord-263258-qpzaehg0	41	39	outcome	outcome	NN
cord-263258-qpzaehg0	41	40	and	and	CC
cord-263258-qpzaehg0	41	41	differences	difference	NNS
cord-263258-qpzaehg0	41	42	in	in	IN
cord-263258-qpzaehg0	41	43	post	post	JJ
cord-263258-qpzaehg0	41	44	-	-	JJ
cord-263258-qpzaehg0	41	45	treatment	treatment	JJ
cord-263258-qpzaehg0	41	46	hospitalisation	hospitalisation	NN
cord-263258-qpzaehg0	41	47	status	status	NN
cord-263258-qpzaehg0	41	48	Compassionate	compassionate	JJ
cord-263258-qpzaehg0	41	49	Use	Use	NNP
cord-263258-qpzaehg0	41	50	of	of	IN
cord-263258-qpzaehg0	41	51	Remdesivir	Remdesivir	NNP
cord-263258-qpzaehg0	41	52	for	for	IN
cord-263258-qpzaehg0	41	53	Patients	patient	NNS
cord-263258-qpzaehg0	41	54	with	with	IN
cord-263258-qpzaehg0	41	55	Severe	Severe	NNP
cord-263258-qpzaehg0	41	56	Covid-19	Covid-19	NNP
cord-263258-qpzaehg0	41	57	Remdesivir	Remdesivir	NNP
cord-263258-qpzaehg0	41	58	in	in	IN
cord-263258-qpzaehg0	41	59	adults	adult	NNS
cord-263258-qpzaehg0	41	60	with	with	IN
cord-263258-qpzaehg0	41	61	severe	severe	JJ
cord-263258-qpzaehg0	41	62	COVID-19	covid-19	NN
cord-263258-qpzaehg0	41	63	:	:	:
cord-263258-qpzaehg0	41	64	a	a	DT
cord-263258-qpzaehg0	41	65	randomised	randomised	JJ
cord-263258-qpzaehg0	41	66	,	,	,
cord-263258-qpzaehg0	41	67	double	double	JJ
cord-263258-qpzaehg0	41	68	-	-	HYPH
cord-263258-qpzaehg0	41	69	blind	blind	JJ
cord-263258-qpzaehg0	41	70	,	,	,
cord-263258-qpzaehg0	41	71	placebo	placebo	NN
cord-263258-qpzaehg0	41	72	-	-	HYPH
cord-263258-qpzaehg0	41	73	controlled	control	VBN
cord-263258-qpzaehg0	41	74	,	,	,
cord-263258-qpzaehg0	41	75	multicentre	multicentre	NNP
cord-263258-qpzaehg0	41	76	trial	trial	NN
cord-263258-qpzaehg0	41	77	the	the	DT
cord-263258-qpzaehg0	41	78	WHO	WHO	NNP
cord-263258-qpzaehg0	41	79	Global	Global	NNP
cord-263258-qpzaehg0	41	80	ICSR	ICSR	NNP
cord-263258-qpzaehg0	41	81	Database	Database	NNP
cord-263258-qpzaehg0	41	82	System	system	NN
cord-263258-qpzaehg0	41	83	:	:	:
cord-263258-qpzaehg0	41	84	Basic	basic	JJ
cord-263258-qpzaehg0	41	85	Facts	fact	NNS
cord-263258-qpzaehg0	41	86	Case	case	NN
cord-263258-qpzaehg0	41	87	-	-	HYPH
cord-263258-qpzaehg0	41	88	non	non	JJ
cord-263258-qpzaehg0	41	89	-	-	JJ
cord-263258-qpzaehg0	41	90	case	case	JJ
cord-263258-qpzaehg0	41	91	studies	study	NNS
cord-263258-qpzaehg0	41	92	:	:	:
cord-263258-qpzaehg0	41	93	Principle	principle	NN
cord-263258-qpzaehg0	41	94	,	,	,
cord-263258-qpzaehg0	41	95	methods	method	NNS
cord-263258-qpzaehg0	41	96	,	,	,
cord-263258-qpzaehg0	41	97	bias	bias	NN
cord-263258-qpzaehg0	41	98	and	and	CC
cord-263258-qpzaehg0	41	99	interpretation	interpretation	NN
cord-263258-qpzaehg0	42	1	The	the	DT
cord-263258-qpzaehg0	42	2	authors	author	NNS
cord-263258-qpzaehg0	42	3	acknowledge	acknowledge	VBP
cord-263258-qpzaehg0	42	4	the	the	DT
cord-263258-qpzaehg0	42	5	Uppsala	Uppsala	NNP
cord-263258-qpzaehg0	42	6	Monitoring	Monitoring	NNP
cord-263258-qpzaehg0	42	7	Centre	Centre	NNP
cord-263258-qpzaehg0	42	8	(	(	-LRB-
cord-263258-qpzaehg0	42	9	UMC	UMC	NNP
cord-263258-qpzaehg0	42	10	)	)	-RRB-
cord-263258-qpzaehg0	42	11	who	who	WP
cord-263258-qpzaehg0	42	12	provided	provide	VBD
cord-263258-qpzaehg0	42	13	and	and	CC
cord-263258-qpzaehg0	42	14	gave	give	VBD
cord-263258-qpzaehg0	42	15	permission	permission	NN
cord-263258-qpzaehg0	42	16	to	to	TO
cord-263258-qpzaehg0	42	17	use	use	VB
cord-263258-qpzaehg0	42	18	the	the	DT
cord-263258-qpzaehg0	42	19	data	datum	NNS
cord-263258-qpzaehg0	42	20	analyzed	analyze	VBN
cord-263258-qpzaehg0	42	21	in	in	IN
cord-263258-qpzaehg0	42	22	the	the	DT
cord-263258-qpzaehg0	42	23	present	present	JJ
cord-263258-qpzaehg0	42	24	study	study	NN
cord-263258-qpzaehg0	42	25	.	.	.
cord-263258-qpzaehg0	43	1	Access	access	NN
cord-263258-qpzaehg0	43	2	to	to	IN
cord-263258-qpzaehg0	43	3	the	the	DT
cord-263258-qpzaehg0	43	4	World	World	NNP
cord-263258-qpzaehg0	43	5	Health	Health	NNP
cord-263258-qpzaehg0	43	6	Organization	Organization	NNP
cord-263258-qpzaehg0	43	7	global	global	JJ
cord-263258-qpzaehg0	43	8	individual	individual	JJ
cord-263258-qpzaehg0	43	9	case	case	NN
cord-263258-qpzaehg0	43	10	safety	safety	NN
cord-263258-qpzaehg0	43	11	report	report	NN
cord-263258-qpzaehg0	43	12	database	database	NN
cord-263258-qpzaehg0	43	13	,	,	,
cord-263258-qpzaehg0	43	14	VigiBase	VigiBase	NNP
cord-263258-qpzaehg0	43	15	®	®	NNP
cord-263258-qpzaehg0	43	16	,	,	,
cord-263258-qpzaehg0	43	17	is	be	VBZ
cord-263258-qpzaehg0	43	18	available	available	JJ
cord-263258-qpzaehg0	43	19	without	without	IN